Immuno-Oncology Therapy (I-O) refers to a therapy that kills tumor cells by activating the body’s immune system. According to their different mechanisms of action, immunotherapeutic drugs can be divided into six categories.Read More…
Immunity：New Antibody Breakthrough to Lead the Fight Against Cancers
In a recent study published in an international magazine of Immunity, scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancers’ defense againstRead More…
Science Advances: The Structure of Antibody IgM Is Redefined
In a new study, researchers from the University of Tokyo in Japan revealed the structure of a immune protein called immunoglobulin M (IgM) by using computer image analysis and electron microscopy imaging.Read More…
Three Scientists from US and UK Shared the 2018 Nobel Prize in Chemistry
On October 3rd, the 2018 Nobel Prize in Chemistry was awarded to the field of biochemistry, in which Frances H. Arnold of US won half in recognition of her directed evolution ofRead More…
Overview of Four Progresses in Antibody Fields
1. DotBio announced the establishment of a next-generation immuno-oncology drug based on domain antibody DotBio, a new company focused on the development of new anti-tumor drugs for humanized antibodies, has officially announcedRead More…
CA: Big Data Analysis Over 85 Years in Anti-cancer Field
The International Union Against Cancer believes that one-third of cancers are preventable, one-third can be cured if diagnosed early, and one-third can be alleviated to help prolong patients’ life. Cancer control isRead More…
First Approval for Erenumab
On May 17, 2018, the U.S. Food and Drug Administration approved erenumab-aooe (Aimovig) for the preventive treatment of migraine in adults. Erenumab is a human monoclonal antibody that targets calcitonin gene-related peptide (CGRP) receptor,Read More…
Combination of Immune Cells Improves Chances of Successful Immunotherapy
Immunotherapy with checkpoint inhibitors is more effective in cancer patients who have elevated numbers of specific types of immune cells inside their tumors, a study suggests. Patients with a favorable combination of immuneRead More…
“Public” T-Cell Receptors from Resistant People Fend Off HIV
The receptors, found in so-called elite controllers who don’t need medications to keep the virus in check, suggest a new path toward immunotherapy. Researchers trying to develop new treatments, or even aRead More…
Overview on Characteristics of Tumor Immunotherapy
Unlike the mechanism of action of traditional treatments, immunotherapy is uniquely characterized by its long-term response and survival in efficacy, unconventional delayed response and pseudo-progression in response mode, a new assessment endpointRead More…